Alpna Seth - Seagen Director
| SGENDelisted Stock | USD 228.74 0.19 0.08% |
Director
Dr. Alpna Seth Ph.D., is Independent Director of Seattle Genetics, Inc., since March 2018. From July 2017 to January 2019, Dr. Seth served as the Chief Operating Officer of Vir Biotechnology, Inc., a publiclytraded biopharmaceutical company. Prior to joining Vir in July 2017, Dr. Seth was Senior Vice President and Global Head of the Biosimilars Global Business Unit for Biogen, Inc. headquartered in Zug, Switzerland since 2014. For the period from 1998 through July 2017, Dr. Seth held a range of leadership roles at Biogen in business development, drug development and commercial, including founding Managing Director of Biogen Idec India and Program Executive for several of Biogens major crossfunctional drug development programs and product launches. Dr. Seth serves as a member of the board of directors of BioTechne Corporationrationration, a publiclytraded biotechnology company. Dr. Seth holds a Ph.D. in Biochemistry and Molecular Biology from University of Massachusetts Medical School and conducted her postdoctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow. She is also a 2002 graduate of the Advanced Management Program at Harvard Business School. Dr. Seth brings a breadth of experience in drug development, commercial, international operations and general management. since 2018.
| Age | 54 |
| Tenure | 6 years |
| Phone | 425 527 4000 |
| Web | https://www.seagen.com |
Seagen Management Efficiency
The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.47 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Seagen Inc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seagen until it has trouble settling it off, either with new capital or with free cash flow. So, Seagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seagen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seagen to invest in growth at high rates of return. When we think about Seagen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Louis Sullivan | United Therapeutics | 84 | |
| Kenneth Bate | Madrigal Pharmaceuticals | 67 | |
| Stephen Glover | PDS Biotechnology Corp | N/A | |
| Kathryn Falberg | Halozyme Therapeutics | 54 | |
| Charles Rowland | Viking Therapeutics | 59 | |
| Katherine Klein | United Therapeutics | 61 | |
| Nilda Mesa | United Therapeutics | 58 | |
| Marsha Fanucci | Alnylam Pharmaceuticals | 64 | |
| DeLyle Bloomquist | PDS Biotechnology Corp | 59 | |
| Daniel Welch | Ultragenyx | 60 | |
| Schond Greenway | Halozyme Therapeutics | N/A | |
| Alan Garber | Exelixis | 62 | |
| Gregory Freitag | PDS Biotechnology Corp | 56 | |
| Steven Paul | Alnylam Pharmaceuticals | 67 | |
| Maria Freire | Exelixis | 63 | |
| Margaret Hamburg | Alnylam Pharmaceuticals | 62 | |
| David Milligan | Madrigal Pharmaceuticals | 77 | |
| Mark Schoenebaum | TG Therapeutics | 45 | |
| George Scangos | Exelixis | 69 | |
| Richard Levy | Madrigal Pharmaceuticals | 60 | |
| Paul Friedman | Madrigal Pharmaceuticals | 75 | |
Management Performance
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 |
Seagen Inc Leadership Team
Elected by the shareholders, the Seagen's board of directors comprises two types of representatives: Seagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seagen. The board's role is to monitor Seagen's management team and ensure that shareholders' interests are well served. Seagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Dansey, Chief Medical Officer | ||
| Vaughn Himes, Executive VP of Process Sciences and Technical Operations | ||
| Daniel Welch, Independent Director | ||
| Felix Baker, Lead Independent Director | ||
| Nancy Simonian, Independent Director | ||
| Peggy Pinkston, IR Contact Officer | ||
| Charles Romp, Ex US | ||
| MS JD, Chief Officer | ||
| Darren Cline, Executive Vice President - Commercial | ||
| Eric Dobmeier, COO, Corporate Secretary | ||
| Todd Simpson, CFO and Principal Accounting Officer | ||
| Pinkston Peggy, Senior Director - Corporate Communications | ||
| David Gryska, Independent Director | ||
| David Caouette, VP Communications | ||
| Srinivas Akkaraju, Independent Director | ||
| Alpna Seth, Director | ||
| Matt Skelton, VP Marketing | ||
| Marc Lippman, Independent Director | ||
| Jonathan Drachman, Chief Medical Officer and Executive Vice President Research and Development | ||
| Jean Liu, Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary | ||
| Robert Lechleider, Senior Vice President - Clinical Development | ||
| Christopher Pawlowicz, Ex HR | ||
| Clay Siegall, Co-Founder, Chairman, CEO and Pres | ||
| Robin Taylor, Chief Commercial Officer | ||
| Dennis Benjamin, Senior Vice President - Translational Research | ||
| Roger MD, Pres RD | ||
| John Orwin, Director | ||
| John McLaughlin, Independent Director |
Seagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.35) % | |||
| Current Valuation | 42.06 B | |||
| Shares Outstanding | 188.66 M | |||
| Shares Owned By Insiders | 0.81 % | |||
| Shares Owned By Institutions | 88.82 % | |||
| Number Of Shares Shorted | 9.58 M | |||
| Price To Earning | 32.75 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seagen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seagen's short interest history, or implied volatility extrapolated from Seagen options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Seagen Inc information on this page should be used as a complementary analysis to other Seagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Seagen Stock
If you are still planning to invest in Seagen Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seagen's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |